The global mantle cell lymphoma treatment market is experiencing a surge, driven by advancements in targeted therapies and immunotherapy. The market is anticipated to reach US$ 2.53 billion in 2024 and expand at a CAGR of 8.6% to reach US$ 5.77 billion by 2034. Key drivers include the increasing incidence of mantle cell lymphoma, personalized medicine approaches, and emerging research in the field.